Literature DB >> 17114080

PET in lymphoma.

Conor D Collins1.   

Abstract

This review attempts to discuss the role of positron emission tomography (PET) imaging for staging, treatment response and follow-up of patients with lymphoma. The pitfalls and impact of PET imaging on the clinical management are also addressed. (c) International Cancer Imaging Society.

Entities:  

Mesh：

Year:  2006        PMID： 17114080      PMCID： PMC1805053          DOI： 10.1102/1470-7330.2006.9013

Source DB:  PubMed          Journal:  Cancer Imaging        ISSN： 1470-7330            Impact factor:   3.909


  79 in total

Review 1.  Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group.

Authors:  B D Cheson; S J Horning; B Coiffier; M A Shipp; R I Fisher; J M Connors; T A Lister; J Vose; A Grillo-López; A Hagenbeek; F Cabanillas; D Klippensten; W Hiddemann; R Castellino; N L Harris; J O Armitage; W Carter; R Hoppe; G P Canellos
Journal:  J Clin Oncol       Date:  1999-04       Impact factor: 44.544

2.  PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin's disease.

Authors:  Lale Kostakoglu; Morton Coleman; John P Leonard; Ichiei Kuji; Holly Zoe; Stanley J Goldsmith
Journal:  J Nucl Med       Date:  2002-08       Impact factor: 10.057

3.  Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging.

Authors:  G Jerusalem; Y Beguin; M F Fassotte; F Najjar; P Paulus; P Rigo; G Fillet
Journal:  Blood       Date:  1999-07-15       Impact factor: 22.113

4.  Response assessment of aggressive non-Hodgkin's lymphoma by integrated International Workshop Criteria and fluorine-18-fluorodeoxyglucose positron emission tomography.

Authors:  Malik E Juweid; Gregory A Wiseman; Julie M Vose; Justine M Ritchie; Yusuf Menda; James E Wooldridge; Felix M Mottaghy; Eric M Rohren; Norbert M Blumstein; Alan Stolpen; Brian K Link; Sven N Reske; Michael M Graham; Bruce D Cheson
Journal:  J Clin Oncol       Date:  2005-04-18       Impact factor: 44.544

5.  Positron emission tomography with 18-fluorodeoxyglucose in the staging and follow-up of lymphoma in the chest.

Authors:  M Bangerter; J Kotzerke; M Griesshammer; K Elsner; S N Reske; L Bergmann
Journal:  Acta Oncol       Date:  1999       Impact factor: 4.089

6.  Comparison between 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography and positron emission tomography/computed tomography hardware fusion for staging of patients with lymphoma.

Authors:  Martin Allen-Auerbach; Andrew Quon; Wolfgang A Weber; Sebastian Obrzut; Tyler Crawford; Daniel H S Silverman; Osman Ratib; Michael E Phelps; Johannes Czernin
Journal:  Mol Imaging Biol       Date:  2004 Nov-Dec       Impact factor: 3.488

7.  Non-Hodgkin lymphoma and Hodgkin disease: coregistered FDG PET and CT at staging and restaging--do we need contrast-enhanced CT?

Authors:  Niklaus G Schaefer; Thomas F Hany; Christian Taverna; Burkhardt Seifert; Katrin D M Stumpe; Gustav K von Schulthess; Gerhard W Goerres
Journal:  Radiology       Date:  2004-07-23       Impact factor: 11.105

8.  Chemotherapy with or without radiotherapy in limited-stage diffuse aggressive non-Hodgkin's lymphoma: Eastern Cooperative Oncology Group study 1484.

Authors:  Sandra J Horning; Edie Weller; KyungMann Kim; John D Earle; Michael J O'Connell; Thomas M Habermann; John H Glick
Journal:  J Clin Oncol       Date:  2004-06-21       Impact factor: 44.544

9.  Early restaging positron emission tomography with ( 18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma.

Authors:  K Spaepen; S Stroobants; P Dupont; P Vandenberghe; J Thomas; T de Groot; J Balzarini; C De Wolf-Peeters; L Mortelmans; G Verhoef
Journal:  Ann Oncol       Date:  2002-09       Impact factor: 32.976

10.  MRI and PET in monitoring response in lymphoma.

Authors:  Alain Rahmouni; Alain Luciani; Emmanuel Itti
Journal:  Cancer Imaging       Date:  2005-11-23       Impact factor: 3.909
View more
  3 in total

Review 1.  PET/CT in oncology: for which tumours is it the reference standard?

Authors:  Conor D Collins
Journal:  Cancer Imaging       Date:  2007-10-01       Impact factor: 3.909

2.  Decoding Intratumoral Heterogeneity of Breast Cancer by Multiparametric In Vivo Imaging: A Translational Study.

Authors:  Jennifer Schmitz; Julian Schwab; Johannes Schwenck; Qian Chen; Leticia Quintanilla-Martinez; Markus Hahn; Beate Wietek; Nina Schwenzer; Annette Staebler; Ursula Kohlhofer; Olulanu H Aina; Neil E Hubbard; Gerald Reischl; Alexander D Borowsky; Sara Brucker; Konstantin Nikolaou; Christian la Fougère; Robert D Cardiff; Bernd J Pichler; Andreas M Schmid
Journal:  Cancer Res       Date:  2016-07-27       Impact factor: 12.701

3.  Intratumoral in vivo staging of breast cancer by multi-tracer PET and advanced analysis.

Authors:  Jennifer Griessinger; Julian Schwab; Qian Chen; Anna Kühn; Jonathan Cotton; Gregory Bowden; Heike Preibsch; Gerald Reischl; Leticia Quintanilla-Martinez; Hidetoshi Mori; An Nguyen Dang; Ursula Kohlhofer; Olulanu H Aina; Alexander D Borowsky; Bernd J Pichler; Robert D Cardiff; Andreas M Schmid
Journal:  NPJ Breast Cancer       Date:  2022-03-24
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.